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Abstract
Background Preoperative randomization for postoperative treatment might affect quality of surgery. In the CRITICS trial 
(ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach), patients were randomized before treatment 
to receive chemotherapy prior to a D1 + gastrectomy (removal of lymph node station (LNS) 1–9 + 11), followed by either 
chemotherapy (CT) or chemoradiotherapy (CRT). In this analysis, the influence of upfront randomization on the quality of 
surgery was evaluated.
Methods Quality of surgery was analyzed in both study arms using surgicopathological compliance (removal of ≥ 15 lymph 
nodes), surgical compliance (removal of the indicated LNS), and surgical contamination (removal of LNS that should be left 
in situ). Furthermore, the ‘Maruyama Index of Unresected disease’ (MI) was evaluated in both study arms, and validated 
with overall survival.
Results Between 2007 and 2015, 788 patients with gastric cancer were included in the CRITICS study of which 636 patients 
were operated with curative intent. No difference was observed between the CT and CRT group regarding surgicopathologi-
cal compliance (74.8% vs 70.9%, P = 0.324), surgical compliance (43.2% vs 39.2%, P = 0.381), and surgical contamination 
(59.4% vs 59.9%, P = 0.567). Median MI was 1 in both groups (range CT 0–88 and CRT 0–136, P = 0.700). A MI below 5 
was associated with better overall survival (CT: P = 0.009 and CRT: P = 0.013).
Conclusion Surgical quality parameters were similar in both study arms in the CRITICS gastric cancer trial, indicating that 
upfront randomization for postoperative treatment had no impact on the quality of surgery. A Maruyama Index below five 
was associated with better overall survival.
Keywords Gastric cancer surgery · Surgical quality · Upfront randomization
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Introduction
Timing of randomization in multimodality trials is often a 
point of debate. This is illustrated by the criticism on the 
timing of randomization in the Intergroup 0116 trial where 
randomization for adjuvant chemoradiotherapy versus no 
adjuvant treatment was done after surgery [1]. Opponents 
found that this moment of randomization may have led to 
selection bias, as pathology results were known at the time 
of selecting patients for the study. Preoperative randomiza-
tion avoids this patients’ selection for study participation 
after surgery.
The US Intergroup 0116 trial and the British MAGIC 
trial changed the current clinical practice for resectable 
gastric cancer in the Western world, by showing a survival 
benefit with adjuvant chemoradiotherapy and periopera-
tive chemotherapy, respectively [1, 2]. As the results of 
the Intergroup 0116 trial and the MAGIC trial were not 
directly comparable due to differences in study design and 
eligibility criteria, the CRITICS trial (ChemoRadiotherapy 
after Induction chemotherapy In Cancer of the Stomach) 
was initiated. In this multicenter trial, patients with resect-
able gastric cancer were treated with three cycles of preop-
erative chemotherapy and surgery with an adequate lymph 
node dissection, followed by either three cycles of chem-
otherapy (CT) or concurrent chemoradiotherapy (CRT). 
Randomization was done before the start of preoperative 
chemotherapy (Fig. 1) [3]. The moment of randomization 
has been criticized. It has been suggested that the qual-
ity of surgery in the CRITICS study might be influenced 
by the knowledge of the treatment that would follow, as 
surgeons were not blinded for the adjuvant therapy. To 
dispel this assumption, the possible influence of upfront 
randomization for the postoperative treatment on the qual-
ity of surgery in the CRITICS trial was investigated in the 
current analyses.
Surgical quality was assessed in both study arms using 
surgicopathological compliance (removal of at least 15 
lymph nodes), surgical compliance (removal of the indicated 
lymph node stations), and surgical contamination (removal 
of lymph node stations that should be left in situ). Fur-
thermore, surgical quality was analyzed by calculating the 
‘Maruyama Index of Unresected disease’ (MI), the strongest 
quality indicator for determining the adequacy of lymphad-
enectomy in gastric cancer surgery. Additionally, the MI was 
validated with overall survival, as in both the Dutch Gastric 
Cancer Trial (DGCT) and the Intergroup 0116 trial, the MI 
proved to be strongly associated with survival, with a cut-off 
value below five for a favorable outcome [4–6]. By analyzing 
these surgical quality parameters in both study arms the aim 
of the current study was to evaluate the possible influence 
of upfront randomization for postoperative treatment on the 
quality of surgery in the CRITICS gastric cancer trial.
Methods
CRITICS protocol
The study protocol of the CRITICS trial has been published 
previously [3]. Patients with a histologically proven stage 
Ib-IVa (AJCC 6th edition) gastric adenocarcinoma were 
included [7]. The bulk of the tumor had to be located in the 
stomach, though extension into the gastro-esophageal junc-
tion (GEJ) was allowed. Patients with ASA classification 1 
or 2 were included. The most important exclusion criteria 
were inoperability, distant metastases, and T1N0 disease 
(determined with endoscopic ultrasound).
Prior to surgery, all patients were assigned to receive 
three cycles of epirubicin, cisplatin/oxaliplatin, and capecit-
abine (ECC/EOC) at 3-weekly intervals. Surgery was sched-
uled 3–6 weeks after the last chemotherapy cycle. The prin-
ciple of surgery was a wide resection of the tumor bearing 
part of the stomach with en bloc removal of lymph nodes 
at stations 1–9 and 11 (D1 + lymph node dissection) and 
with a minimum of 15 lymph nodes. A D1 + was chosen 
with best insight while the discussion regarding the extent 
of lymphadenectomy for gastric cancer in the Western world 
was still ongoing at the moment of designing the trial. A D1 
lymph node dissection was defined as removal of stations 
3–6 during subtotal gastrectomy and stations 1–6 during 
total gastrectomy. A D2 lymph node dissection was defined 
as removal of stations 1,3, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, and 
12a during subtotal gastrectomy and stations 1–7, 8a, 9, 10, 
11p, 11d, and 12a during total gastrectomy [8]. Adjacent 
organs were only removed if there was suspicion of tumor 
involvement. If possible, a macroscopic margin of 5 cm was 
obtained, both to the proximal end and to the distal end. For 
tumors in the upper part of the stomach, a total gastrectomy 
Fig. 1  Design of the CRITICS trial. R randomization, Chemother-
apy epirubicin, cisplatin/oxaliplatin, and capecitabine (ECC/EOC), 
D1 + surgery surgery including a D1 + lymphadenectomy, Chemora-
diotherapy 45 Gy/25 fractions + capecitabine + cisplatin
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was performed. For tumors in the middle or distal part of the 
stomach, a subtotal resection of the stomach was performed, 
leaving lymph node stations 2 and 4 s in situ. A transhiatal 
esophagus-cardia resection with gastric tube reconstruction 
was performed for gastro-esophageal junction (GEJ) tumors 
extending into the esophagus, leaving lymph node stations 
4d and 6 in situ. Both open and minimally invasive proce-
dures were allowed.
After surgery, the study protocol dictated either another 
three courses of ECC/EOC (CT) or chemoradiotherapy 
(CRT; 45 Gy in 25 fractions combined with daily capecit-
abine and weekly cisplatin). Randomization of the adjuvant 
therapy occurred prior to the start of treatment (Fig. 1).
Surgical quality assurance in the CRITICS trial
Before participation in the CRITICS trial, a presentation was 
given to instruct surgeons which lymph node stations had to 
be removed according to the study protocol. Participating 
surgeons also received a DVD and a book with instructions 
as well. Continuous quality assurance was carried out since 
2011 and included regular feedback to the participating sur-
geon and pathologist on their average lymph node count in 
the trial, together with the average lymph node count in the 
study at that moment. In addition, if the study coordina-
tor received a report with a lymph node count below 15, 
feedback was provided within 3 months after surgery to the 
respective surgeon and pathologist and if possible, the sur-
gical specimen was examined for remaining lymph nodes.
Eligibility current study
For the current analyses, patients were selected from the 
CRITICS database if the gastric cancer operation was per-
formed with curative intent, based on the surgical report.
Patients were excluded from the surgicopathological 
analyses if the total number of sampled lymph nodes was 
not documented by the pathologist. Patients were excluded 
from the analyses of surgical compliance, surgical contami-
nation, and MI, if the exact location of the directed lymph 
node stations was not extractable from the surgical report.
This study was reported according the CONSORT 2010 
statement [9].
Central data review
Data on the dissected lymph node stations (1–16) and type of 
lymph node dissection (D1 + or more) were extracted from 
the surgical reports, supplementary to the data recorded in 
the CRF. These data were validated and optimized by two 
experienced gastric surgeons. In case the number of removed 
lymph node stations was not explicitly stated in the surgical 
report, an assumption was made based on the mentioned 
anatomical structures in the surgical report, if possible. For 
example, when a given surgical report described the removal 
of lymph nodes along the common hepatic artery, it was 
revised as the removal of lymph node station 8. If assump-
tions were not possible, it was scored as unknown. In case 
all stations were unknown, patients were excluded from the 
analyses. In case a single lymph node station was unknown, 
the station was considered as not removed.
Surgicopathological compliance
Surgicopathological compliance was defined as the removal 
of a minimum of 15 lymph nodes and surgicopathological 
non-compliance as the removal of less than 15 lymph nodes. 
The latter group was divided into minor surgicopathological 
non-compliance, defined as the removal of a minimum of 
10 lymph nodes, and major surgicopathological non-com-
pliance, defined as the removal of less than 10 lymph nodes.
Surgical compliance and surgical contamination
Surgical compliance was defined as the removal of stations 
1–9 and 11, except for subtotal gastric resections where 
lymph node stations 2 and 4 s were left in situ, and esoph-
agus-cardia resections where lymph node stations 4d and 6 
were left in situ. The definition of surgical non-compliance 
was not harvesting all indicated lymph node stations. The 
surgical non-compliance group was divided into minor non-
compliance (1 or 2 of the intended lymph node stations not 
removed) and major non-compliance (≥ 3 of the intended 
lymph node stations not removed).
Surgical contamination was defined as removal of one 
or more lymph node stations outside the intended extent of 
resection. Surgical contamination was subdivided into minor 
contamination (1 or 2 lymph node stations that should be 
left in situ removed) and major contamination (≥ 3 lymph 
node stations that should be left in situ removed). Surgical 
compliance and surgical contamination were based on the 
data validated by two experienced gastric surgeons.
Maruyama index
The MI is based on eight parameters: sex, age, type of cancer 
(early or advanced), depth of invasion, maximal diameter, 
location (upper third, middle third, lower third), position 
(lesser curvature, greater curvature, anterior, posterior, cir-
cular), and histological type. In the current study, the MI 
was determined using the Maruyama Computer Program. 
To quantify the likelihood of unresected nodal disease, the 
MI is defined as the sum of Maruyama Computer Program 
predictions for the regional lymph node stations 1–12, which 
were not removed by the surgeon. When a given patient 
underwent a total gastrectomy with removal of lymph node 
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stations 1–7 and 9, the MI was calculated by adding up the 
likelihood of unresected nodal disease at stations 8, 10, 11, 
and 12.
Statistics
The chi-squared test was used to compare categorical data 
between the CT and CRT group and the unpaired t test was 
used for numerical data. Overall survival since surgery for 
both study arms was estimated by the Kaplan–Meier method 
and survival distribution of MI (< 5 and ≥ 5) was assessed by 
the log-rank test. The effect of MI (< 5 and ≥ 5) on survival 
in both groups was determined by an interaction test. A P 
lower than 0.05 was considered as statistically significant. 
SPSS program 21.0 was used for statistical analyses.
Results
From January 2007 to April 2015, 788 patients were 
included at 56 centers in the Netherlands, Sweden, and Den-
mark. For current analyses, 636 patients were eligible; 632 
patients for the analyses on surgicopathological compliance, 
622 patients for the analyses on surgical compliance, surgi-
cal contamination, MI, and MI and survival (Fig. 2).
Patient characteristics are shown in Table 1. The localiza-
tion of the primary tumor (proximal, middle, distal stomach) 
was equally distributed in the CT group and in the CRT 
group. In both groups, the majority of patients underwent a 
total gastrectomy, followed by a subtotal gastrectomy, and 
an esophagus-cardia resection. In the CT group, 22 patients 
underwent a splenectomy (7.1%) compared to 16 patients 
(4.9%) in the CRT group. The rate of distal pancreatectomies 
was low in both groups, 6 patients (1.9%) in the CT group 
and 10 patients (3.1%) in the CRT group, respectively.
Surgicopathological compliance occurred in 230 patients 
(74.8%) in the CT group and 232 patients (70.9%) in the 
CRT group (P = 0.324, Fig. 3a). Surgicopathological com-
pliance improved over time both in the CT group (from 60.0 
to 100%) and in the CRT group (from 50.0 to 80.0%). No 
significant difference was observed between the CT group 
and the CRT group with respect to at least a D1 + lymphad-
enectomy performed (88.8% vs 86.2%, P = 0.333). Complete 
surgical compliance occurred in 131 patients (43.2%) in the 
CT group and in 125 patients (39.2%) in the CRT group 
(P = 0.381, Fig. 3b). Similarly, surgical contamination was 
not different between the two study arms (Fig. 3c).
Median MI was 1 in both the CT group (range 0–88) 
and the CRT group (range 0–136, P = 0.700). A MI < 5 
was associated with an improved overall survival in both 
groups (Fig. 4). The effect of MI < 5 on survival did not 
Fig. 2  Study flow chart
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Table 1  Patient characteristics
Age and median n# of LN dissected is presented as median (range), other data are presented as n (%)
CT group chemotherapy, CRT group chemoradiotherapy, median n# LN dissected median number of lymph 
nodes dissected
CT group (n = 310) CRT group (n = 326) P
Median age (years) 61.5(28–81) 63.0 (30–82) 0.240
Sex
 Male 214 (69.0) 215 (66.0) 0.359
 Female 96 (31.0) 111 (34.0)
Lauren classification
 Diffuse 101 (32.6) 105 (32.2) 0.712
 Intestinal 88 (28.4) 87 (26.7)
 Mixed 13 (4.2) 21 (6.4)
 Unknown 108 (34.8) 112 (34.7)
Tumor localization
 Proximal stomach 116 (37.8) 120 (36.8) 0.655
 Middle stomach 95 (30.7) 88 (27.0)
 Distal stomach 99 (31.6) 118 (36.2)
Type of resection
 Total gastrectomy 159 (51.3) 159 (48.8) 0.688
 Subtotal gastrectomy 119 (38.4) 136 (41.7)
 Esophagus-cardia resection 32 (10.3) 31 (9.5)
Tumor stage
 pT0/pTis/pT1 62 (20.0) 71 (21.8) 0.882
 pT2 108 (34.8) 114 (35.0)
 pT3 110 (35.5) 107 (32.8)
 pT4 30 (9.7) 34 (10.4)
Node stage
 pN0 150 (48.4) 161 (49.4) 0.846
 pN1 109 (35.1) 105 (32.2)
 pN2 35 (11.3) 42 (12.9)
 pN3 16 (5.2) 18 (5.5)
UICC stage
 Stage 0 21 (6.8) 22 (6.7) 0.373
 Stage 1 100 (32.3) 101 (31.0)
 Stage 2 65 (21.0) 84 (25.8)
 Stage 3 87 (28.1) 73 (22.4)
 Stage 4 37 (11.9) 46 (14.1)
Splenectomy
 Yes 22 (7.1) 16 (4.9) 0.244
 No 288 (92.9) 310 (95.1)
Distal pancreatectomy
 Yes 6 (1.9) 10 (3.1) 0.489
 No 304 (98.1) 316 (96.9)
Approach
 Open 256 (82.6) 274 (84.0) 0.837
 Minimally invasive 46 (14.8) 43 (13.2)
 Conversion 6 (1.9) 6 (1.8)
 Unknown 2 (0.7) 3 (1.0)
Surgical complication
 Yes 70 (22.6) 72 (22.1) 0.880
 No 240 (77.4) 254 (77.9)
Median n# LN dissected 21 (0–72) 19 (0–71) 0.037
Radicality
 R0 248 (80.0) 267 (81.9) 0.828
 R1 34 (11.0) 32 (9.8)
 Unknown 28 (9.0) 27 (8.3)
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differ between the two groups (HR: 1.06; 95% CI: 0.67–1.69; 
P = 0.793).
Discussion
In the CRITICS trial, gastric cancer patients were rand-
omized before start of the treatment between adjuvant chem-
otherapy (CT) and adjuvant chemoradiotherapy (CRT) after 
preoperative chemotherapy and surgery. In the current study, 
the potential effect of upfront randomization for postopera-
tive treatment on the quality of surgery was evaluated. No 
significant differences were observed between the CT and 
the CRT group with regard to a number of surgical qual-
ity parameters. A Maruyama Index, one of the most potent 
quality parameters in gastric cancer surgery, below 5 was 
associated with an improved overall survival in both groups.
The CRITICS trial was designed based on two rand-
omized trials, the Intergroup 0116 trial and the MAGIC trial 
that changed current clinical practice in the Western world 
for locally advanced resectable gastric cancer by showing 
an improved survival with postoperative chemoradiotherapy 
and perioperative chemotherapy, respectively [1, 2]. In the 
Intergroup 0116 trial, patients were randomized 20–40 days 
after surgery, for postoperative chemoradiotherapy versus 
no adjuvant treatment. The study has been criticized for the 
fact that only 10% of the patients underwent the intended 
D2 lymph node dissection [1]. In the CRITICS trial in 73% 
of the patients, at least 15 lymph nodes were removed and 
around 41% of the patients underwent the intended D1 + dis-
section (surgical compliance) [10]. Although the latter 
finding is an improvement compared to the number of the 
Intergroup 0116 trial, surgical compliance in the CRITICS 
trial might have been expected to be higher due to the strict 
quality assurance program within the trial. However, when 
interpreting the surgical compliance rate in the CRITICS 
trial some aspects should be taken into account. First, surgi-
cal compliance is probably an underestimation, as ‘unknown 
lymph node station’ was considered ‘not removed’. Fur-
thermore, in contrast to the Eastern world, lymph nodes of 
different lymph node stations in the Western world are not 
separately removed by the surgeon. As a consequence, the 
removal of specific lymph node stations is less recorded in 
surgery reports and all lymph nodes together are offered to 
the pathologist instead of lymph nodes from each specific 
lymph node station. The number of lymph nodes is therefore 
probably of more value than the surgical compliance rate.
Postoperative randomization such as in the Intergroup 
0116 trial harbors the risk of selection bias, as only a propor-
tion of patients will be able to start postoperative treatment. 
These patients may reflect a selection of younger, physically 
more fit patients with a good performance status, leading to 
a possible overestimation of the survival benefit. The extent 
of this selection will be considerable because it is known 
that after gastric cancer surgery a significant proportion of 
patients will never start, due to disease progression, postop-
erative complications, poor condition, refusal of patients, or 
even death. In the CRITICS trial, 61% of the patients in the 
CT group and 63% in the CRT group started postoperative 
treatment and 47% (CT group) and 54% (CRT group) was 
able to complete adjuvant therapy, respectively [11]. This is 
comparable to other gastric cancer trials as the Intergroup 
0116 trial and the French FNCLCC and FFCD trial where 
63% and 50% of the patients completed treatment accord-
ing the study protocol, respectively [1, 12]. In the MAGIC 
trial, 66% of the patients commenced with postoperative 
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chemotherapy and 43% of the patients managed to complete 
adjuvant treatment [2]. In this trial, patients were randomly 
assigned to either perioperative chemotherapy and surgical 
resection or to surgical resection alone, 6 weeks prior to sur-
gery. With this design, insight is gained in the whole chain 
of multimodal treatments, thus more accurate information 
can be given to the patients’ options. This applies for rand-
omized clinical trials with multimodal treatment routes; in 
general, however, in gastric cancer trials, this is even more 
important because the proportion of patients who do not 
complete the whole chain is substantial.
In the CRITICS trial, as in the MAGIC trial, patients 
were randomized for postoperative treatment before the start 
of treatment; either three additional courses of chemotherapy 
or chemoradiotherapy. It was decided to randomize prior 
to preoperative treatment to prevent selection of patients 
after surgery, which might bias the inclusion. Opponents 
have considered the preoperative randomization as a pos-
sible limitation of the CRITICS trial for the reason that this 
could influence the quality of surgery. These assumptions 
suggest that the surgical performance was influenced by the 
knowledge of the result of the randomization, as participat-
ing surgeons were not blinded for the adjuvant treatment. For 
instance, a surgeon might decide to perform a more extended 
lymphadenectomy in case a patient was randomized for 
‘only’ chemotherapy instead of chemoradiotherapy.
Results of the current study showed no significant dif-
ferences between the CRT and the CT group with regard 
to surgicopathological compliance, number of adequate 
lymphadenectomies performed, surgical compliance, and 
surgical contamination. Both groups had a median MI of 
1. Altogether, there are no indications that upfront rand-
omization for postoperative treatment in the CRITICS trial 
was associated with differences in the quality of surgery. 
Thereby, the primary outcomes of the CRITICS trial, over-
all survival and progression-free survival, can be compared 
more reliably between both arms, whereby more trustworthy 
conclusions can be drawn about the possible added effect of 
adjuvant therapy in patients with locally advanced resectable 
gastric cancer.
In the MAGIC trial, detailed information about the qual-
ity of surgery was lacking, and in the Intergroup 0116 trial, 
the proportion of adequate gastric cancer resections was low. 
The strength of the current study was the very detailed infor-
mation on the quality of surgery, and it shows the success 
of the surgical quality assurance within the CRITICS trial.
The design of the CRITICS trial, including the upfront 
randomization, has its limitations. Inherent to this design, 
the number of randomized patients who completed the full 
multimodal treatment was around 50%, in both arms, leading 
to a possible underestimation of the treatment effect. On the 
other hand, this design provides insight in the entire chain of 
multimodal treatments for gastric cancer patients and reflects 
daily practice in treating Western gastric cancer patients.
In conclusion, our analyses indicate that upfront rand-
omization for postoperative treatment did not influence the 
quality of surgery in the CRITICS trial. A Maruyama Index 
below five was associated with a better survival.
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